Medicines labeled for the same conditions
Alternatives to panitumumab
8 other medicines are given the same way (intravenous) and in the same FDA class as panitumumab or labeled mainly for the same use (colorectal cancer); 1 is in its class, epidermal growth factor receptor antagonists: cetuximab; the others include 3 vascular endothelial growth factor inhibitors, 1 platinum-based drug and 1 nucleoside metabolic inhibitor (FDA labels read October 8, 2026).
Which medicines are labeled for the same conditions as panitumumab?
Colorectal cancer lists all 23 medicines labeled for it, by any route. Each row shows the conditions both labels name. They are listed as public records, not as substitutes: whether one can replace another depends on the person and is a prescriber's decision.
| Medicine and FDA class | Shared indication | Generic labelers (intravenous) | Pharmacy cost | Boxed warning | Shortage |
|---|---|---|---|---|---|
| Panitumumabepidermal growth factor receptor antagonist | this medicine | none listed | n/a | Yes | No current entry |
| Cetuximabepidermal growth factor receptor antagonist · same class | Colorectal cancer | none listed | n/a | Yes | No current entry |
| Oxaliplatinplatinum-based drug | Colorectal cancer | 17 labelers | n/a | Yes | A presentation being discontinued |
| Fluorouracilnucleoside metabolic inhibitor | Colorectal cancer | 12 labelers | n/a | Yes | No current entry |
| Irinotecantopoisomerase inhibitor | Colorectal cancer | 12 labelers | n/a | Yes | A presentation being discontinued |
| Levoleucovorinfolate analog | Colorectal cancer | 8 labelers | n/a | No | No current entry |
| Bevacizumabvascular endothelial growth factor inhibitor | Colorectal cancer | none listed | n/a | No | No current entry |
| Afliberceptvascular endothelial growth factor inhibitor | Colorectal cancer | none listed | n/a | No | No current entry |
| Bevacizumab-malyvascular endothelial growth factor inhibitor | Colorectal cancer | none listed | n/a | No | No current entry |
Source: FDA drug labels (indications) via openFDA; FDA NDC Directory; CMS NADAC of October 7, 2026; FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Panitumumab: the full record
- label, generics, price, shortages, recalls